Belzutifan has shown objective response in the treatment of adult patients with VHL-related tumors, certain advanced RCC, and PPGL aged 12 years and older, delaying disease progression.
Von Hippel-Lindau (VHL) Disease:
For the treatment of adult patients with von Hippel-Lindau (VHL) disease who require treatment for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastoma, or pancreatic neuroendocrine tumor (pNET) without immediate surgical intervention.
Advanced Renal Cell Carcinoma (RCC):
For the treatment of adult patients with advanced renal cell carcinoma (RCC) whose tumors have a clear cell component and who have experienced disease progression after treatment with programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) inhibitors and vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs).
Pheochromocytoma or paraganglioma (PPGL)
Is used to treat locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL) in adult and pediatric patients aged 12 years and older.
